IBDEI3AK ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52531,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,52531,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,52532,0)
 ;;=I12.9^^194^2541^4
 ;;^UTILITY(U,$J,358.3,52532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52532,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,52532,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,52532,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,52533,0)
 ;;=I13.0^^194^2541^8
 ;;^UTILITY(U,$J,358.3,52533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52533,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,52533,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,52533,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,52534,0)
 ;;=I13.10^^194^2541^10
 ;;^UTILITY(U,$J,358.3,52534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52534,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,52534,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,52534,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,52535,0)
 ;;=I13.11^^194^2541^11
 ;;^UTILITY(U,$J,358.3,52535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52535,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,52535,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,52535,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,52536,0)
 ;;=I13.2^^194^2541^9
 ;;^UTILITY(U,$J,358.3,52536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52536,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,52536,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,52536,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,52537,0)
 ;;=I15.0^^194^2541^15
 ;;^UTILITY(U,$J,358.3,52537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52537,1,3,0)
 ;;=3^Renovascular Hypertension
 ;;^UTILITY(U,$J,358.3,52537,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,52537,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,52538,0)
 ;;=I15.1^^194^2541^3
 ;;^UTILITY(U,$J,358.3,52538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52538,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,52538,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,52538,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,52539,0)
 ;;=I15.2^^194^2541^2
 ;;^UTILITY(U,$J,358.3,52539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52539,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,52539,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,52539,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,52540,0)
 ;;=I15.8^^194^2541^16
 ;;^UTILITY(U,$J,358.3,52540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52540,1,3,0)
 ;;=3^Secondary Hypertension,Oth
 ;;^UTILITY(U,$J,358.3,52540,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,52540,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,52541,0)
 ;;=I15.9^^194^2541^17
 ;;^UTILITY(U,$J,358.3,52541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52541,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,52541,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,52541,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,52542,0)
 ;;=I16.0^^194^2541^14
 ;;^UTILITY(U,$J,358.3,52542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52542,1,3,0)
 ;;=3^Hypertensive Urgency
 ;;^UTILITY(U,$J,358.3,52542,1,4,0)
 ;;=4^I16.0
 ;;^UTILITY(U,$J,358.3,52542,2)
 ;;=^8133013
 ;;^UTILITY(U,$J,358.3,52543,0)
 ;;=I16.1^^194^2541^7
 ;;^UTILITY(U,$J,358.3,52543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52543,1,3,0)
 ;;=3^Hypertensive Emergency
 ;;^UTILITY(U,$J,358.3,52543,1,4,0)
 ;;=4^I16.1
